Ekso Bionics shares surge 53.85% premarket after announcing merger with Applied Digital to form AI-focused ChronoScale.

Ekso Bionics (EKSO) surged 53.85% in premarket trading following the announcement of a proposed merger with Applied Digital’s cloud computing business to form ChronoScale, an AI-optimized compute platform. The deal, expected to close by mid-2026, would see Applied Digital own 97% of the combined entity, which aims to address growing demand for GPU-accelerated infrastructure. The strategic move aligns with EKSO’s exploration of strategic alternatives and leverages Applied Digital’s early adoption of NVIDIA H100 GPUs. Despite Q2 2025 revenue declining to $2.1 million and a $0.54 loss per share, the merger’s focus on high-performance computing for AI workloads and potential operational scalability drove the sharp premarket rally, overshadowing near-term financial underperformance.